Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Accumulated Depreciation (2020 - 2025)

Bolt Biotherapeutics' Accumulated Depreciation history spans 5 years, with the latest figure at $7.3 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation rose 26.53% year-over-year to $7.3 million; the TTM value through Dec 2024 reached $7.3 million, up 26.53%, while the annual FY2024 figure was $7.3 million, 26.53% up from the prior year.
  • Accumulated Depreciation for Q4 2024 was $7.3 million at Bolt Biotherapeutics, up from $6.9 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $7.3 million in Q4 2024 and bottomed at $1.2 million in Q4 2020.
  • The 5-year median for Accumulated Depreciation is $4.4 million (2023), against an average of $4.4 million.
  • The largest annual shift saw Accumulated Depreciation surged 81.19% in 2021 before it increased 26.53% in 2024.
  • A 5-year view of Accumulated Depreciation shows it stood at $1.2 million in 2020, then soared by 81.19% to $2.2 million in 2021, then soared by 74.39% to $3.9 million in 2022, then surged by 46.92% to $5.8 million in 2023, then increased by 26.53% to $7.3 million in 2024.
  • Per Business Quant, the three most recent readings for BOLT's Accumulated Depreciation are $7.3 million (Q4 2024), $6.9 million (Q3 2024), and $6.2 million (Q1 2024).